2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 652

Clinical Relevance According to Staining Patterns and Titers of Antinuclear Antibody

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 515

Clinical Responses in Patients with Inadequate Response to bDMARDs upon Treatment with Upadacitinib

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 791

Closing the Seronegative Gap in Pediatric Localized Scleroderma and Systemic Sclerosis

Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

9:00AM-11:00AM: Abstract Number: 676

Cluster Profiling of Patients in a Real-World Data Set with Systemic Lupus Erythematosus and Their Associated Treatments

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 360

Colchicine Prophylaxis of Gout Flares When Commencing Allopurinol Is Very Cost Effective: A Health Economic Analysis

Metabolic & Crystal Arthropathies Poster I: Clinical

9:00AM-11:00AM: Abstract Number: 245

Comorbidities, Health Care Utilization, and Cost of Care in Systematic Lupus Erythematous Increase with Disease Severity During 1 Year Before and After Diagnosis: A Real-World Cohort Study in the United States, 2004–2015

Health Services Research Poster I – ACR/ARP

9:00AM-11:00AM: Abstract Number: 20

Comparative Efficacy of Beta-2-Glycoprotein I Domain V Structural Analogue Variants in Preventing Antiphospholipid Antibody-Mediated Endothelial Cell Activation

Cytokines & Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 355

Comparative Risk of Cardiovascular Events in US Veterans with Gout Treated with Febuxostat versus Allopurinol

Metabolic & Crystal Arthropathies Poster I: Clinical

9:00AM-11:00AM: Abstract Number: 241

Comparing Patients with Fibromyalgia Syndrome with Non-Fibromyalgia Rheumatic Disease Patients Regarding Exercise

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 540

Comparing Real-world Retention Rates in a Matched Cohort of Rheumatoid Arthritis Patients Who Either Remained on the Etanercept Originator or Switched to a Biosimilar

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 557

Comparing Symptoms, Treatments Patterns, and Quality of Life of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Patients: Findings from a US Survey

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 182

Comparing the Generalizability of Cardiovascular Risk in Different Rheumatoid Arthritis Cohorts

Epidemiology & Public Health Poster I: RA

9:00AM-11:00AM: Abstract Number: 279

Comparison of Carotid Ultrasound and Coronary Artery Calcium Score in Cardiovascular Risk Stratification of Patients with Inflammatory Rheumatic Diseases

Imaging Of Rheumatic Diseases Poster I

9:00AM-11:00AM: Abstract Number: 485

Comparison of Clinical Features, Synovial Histology and Immunohistochemistry in Seropositive Arthralgia, Rheumatoid Arthritis, and Osteoarthritis

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 150

Comparison of Debate vs. Lecture to Teach Medical Students Pediatric Rheumatology

Education Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].